Cogent Biosciences files prospectus for up to $400 million in at-the-market stock sales
Cogent Biosciences filed a prospectus supplement on August 10, 2026, covering the offer and sale of up to $400,000,000 of common stock through Guggenheim Securities under an existing sales agreement. The offering runs under an automatic shelf registration statement filed November 7, 2025, and the filing does not state a price or timing for any sales. For shareholders, this sets up a possible source of new shares that could dilute existing holdings if sold.
Key points
- Up to $400,000,000 of common stock may be sold through Guggenheim Securities, as sales agent or principal, at market prices.
- The prospectus supplement was filed August 10, 2026, under Form S-3ASR (File No. 333-291384).
- Gibson, Dunn & Crutcher LLP issued a legal opinion on the shares (Exhibit 5.1).
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.